abstract |
The present invention provides anti-HLA-DR monoclonal antibodies. The present invention binds to HLA-DR having the property of (a) showing a life-prolonging effect in a non-human animal carrying HLA-DR-expressing cancer cells and (b) having a weak inhibitory activity against an immune reaction as compared with L243. An antibody or a functional fragment thereof, an antibody that binds to HLA-DR that exhibits an immunosuppressive activity that is equivalent to or stronger than L243 compared to mouse anti-HLA-DR monoclonal antibody L243 (ATCC HB-55), or a functional thereof It is a fragment. |